Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial
- Submitting institution
-
The University of Leeds
- Unit of assessment
- 2 - Public Health, Health Services and Primary Care
- Output identifier
- UOA2-1681
- Type
- N - Research report for external body
- DOI
-
10.3310/hta21280
- Commissioning body
- NIHR Health Technology Assessment Programme
- Month
- May
- Year
- 2017
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
11
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- Contribution A: Contribution to the conception and design of the study,Contribution to carrying out the study,Contribution to analysis and interpretation of the study data
Contribution B: The author helped draft the output,Critique the output for important intellectual content
- Non-English
- No
- English abstract
- -
